Skip to main content
Explore URMC

IGUP20133 / Van Veldhuizen / ARC-6

Basic Study Information

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Location: Wilmot Cancer Institute Oncology, University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Peter Van Veldhuizen

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search